Lumida
/PRVA
⌘K
Privia Health Group Inc

Privia Health Group Inc

PRVA
$20.42USD+0.25%+0.05 today

MARKET CAP

2.6B

P/E (TTM)

127.6x

FWD P/E

DAY RANGE

$20 – $21

52W RANGE

$20
$29

AI Summary

Stalk
Buy NowMedium

PRVA has formed a clear Post-Capitulation mean-reversion pattern with tight absorption candles and reduced volume, suggesting forced selling is exhausted. With the stock deeply oversold and RSI turning up, timing now is favorable for a tactical buy into the support cluster. Medium-term mean-reversion permission anchors a bullish bias, while long-term uptrend remains intact. We target the absorption zone and shallow pullback into short-term EMAs for entry.

  • Q2 revenue reached $632.6M (+21.4% YoY), topping analyst estimates.
  • Net income surged 237% YoY to $9M, with adjusted EPS $0.19.
  • Complexity of state rollouts intensifies execution and integration risks.
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$966.2M$1.4B$1.7B$1.7B$2.1B
YoY %+40.4%+22.2%+4.7%+22.3%
P / Sales2.8x1.8x1.8x1.4x1.4x
EV / Sales2.7x1.8x1.8x1.4x1.5x
Gross Profit, Adj.$791.5M$1.2B$1.5B$1.5B$1.9B
YoY %+49.8%+23.1%+3.4%+23.9%
Margin %81.9%87.4%88.1%86.9%88.1%
EV / Gross Profit3.3x2.0x2.0x1.6x1.7x
EBITDA, Adj.$512.9M$1.0B$1.3B$1.4B$1.7B
YoY %+102.1%+27.9%+2.3%+25.7%
Margin %53.1%76.4%80.0%78.1%80.3%
EV / EBITDA5.0x2.3x2.2x1.8x1.9x
EBIT$510.4M$1.0B$1.3B$1.3B$1.7B
YoY %+102.2%+27.8%+2.3%+25.6%
Margin %52.8%76.1%79.6%77.7%79.8%
EV / EBIT5.1x2.3x2.2x1.8x1.9x
Net Income$-188.2M$-8.6M$23.1M$14.4M$22.9M
YoY %+95.4%+368.8%-37.7%+59.3%
Net Margin-19.5%-0.6%1.4%0.8%1.1%
EPS (GAAP)-$1.83-$0.08$0.19$0.11$0.18
YoY %+95.6%+337.5%-42.1%+63.6%